Argenica Therapeutics commences preparations for phase 1 clinical trial of stroke-treatment drug ARG-007

smallcaps.com.au
2 min read
difficult
Biotechnology company Argenica Therapeutics (ASX: AGN) has engaged Perth-based company Linear Clinical Research to initiate preliminary work required for a phase 1 trial into the safety and tolerability of stroke-treatment drug ARG-007 on healthy human subjects.
Linear's work will comprise study start-up activities including protocol familiarisation, clinical site management setup, preparation of ethics submission, booking clinical beds for the length of the trial, and establishing the clinical study monitoring.

The company has a purpose-built facility at QEII Medical Centre and a database of around 29,000 healthy volunteers which will be used as a recruitment pool for the trial.

Since 2010, it has conducted over 170 studies across 19 therapeutic areas and has extensive experience in phase 1 trials, including adaptive healthy volunteer and patient protocol designs.

Ideal partner

Argenica chief executive officer Dr Liz Dallimore said Linear was the ideal partner to help progress the new trial.

"Linear has fantastic credentials in…
Imelda Cotton Has Over Years Experience As A Journalist, Communications Professional. She Has Spent The Bulk Of Her Career In The Resources Sector, Having Also Worked Directly With Oil, Gas Majors, As A Journalist Covering A Vast Array Of Asx Listed Companies Within The Resources, Energy, Science, Health Sectors.
Read full article